PFG Investments LLC Trims Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

PFG Investments LLC trimmed its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 10.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 347,747 shares of the biotechnology company’s stock after selling 38,700 shares during the quarter. PFG Investments LLC owned 0.58% of Aldeyra Therapeutics worth $1,735,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. US Bancorp DE purchased a new stake in Aldeyra Therapeutics in the third quarter worth about $30,000. Paloma Partners Management Co bought a new stake in shares of Aldeyra Therapeutics in the 3rd quarter valued at about $62,000. King Wealth Management Group boosted its stake in shares of Aldeyra Therapeutics by 24.5% during the third quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 2,700 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Aldeyra Therapeutics by 253.3% during the third quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 10,201 shares during the period. Finally, Intech Investment Management LLC bought a new position in Aldeyra Therapeutics in the third quarter worth approximately $79,000. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Stock Performance

Aldeyra Therapeutics stock opened at $5.03 on Tuesday. Aldeyra Therapeutics, Inc has a twelve month low of $2.71 and a twelve month high of $6.55. The business has a fifty day moving average of $4.98 and a two-hundred day moving average of $5.05. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.25). On average, research analysts predict that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.